Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 5764227

Next Previous
Drug Profile

GSK 5764227

Alternative Names: GSK-5764227; GSK’227; HS-20093

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hansoh Biomedical
  • Developer GSK; Hansoh BioMedical R&D Company; Shanghai Hansoh Biomedical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase II Head and neck cancer; Oesophageal cancer; Osteosarcoma; Prostate cancer; Sarcoma; Solid tumours
  • Phase I/II Gastrointestinal cancer
  • Phase I Colorectal cancer

Most Recent Events

  • 11 Aug 2025 Hansoh BioMedical R&D Company plans a phase I trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater, Late-stage disease) in August 2025 (IV) (NCT07115446)
  • 08 Aug 2025 GSK plans a phase III trial for Small cell lung cancer (Second-line therapy or greater, Late-stage disease) (Parenteral), in August 2025 (NCT07099898)
  • 21 Jul 2025 NCT07063407 - FET

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top